Charts
From 02/05/2022 our Markets Data content will no longer be free to read. To continue to get full access, subscribe now and receive 25% off.
Equities

Zydus Lifesciences Ltd

ZYDUSLIFE:NSI

Zydus Lifesciences Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (INR)953.00
  • Today's Change-11.90 / -1.23%
  • Shares traded428.47k
  • 1 Year change+49.14%
  • Beta0.3912
Data delayed at least 15 minutes, as of Nov 26 2024 10:16 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Zydus Lifesciences Limited is an India-based global life sciences company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The Company is engaged in the business of integrated pharmaceutical operations. Its product portfolio includes active pharmaceutical ingredients (API), human formulations, animal health and veterinary, health, and wellness products. Its products include India formulations, Generics and Zydus biologics. The Company's products include Lipaglyn and Bilypsa (Saroglitazar), Ujvira (Trastuzumab emtansine biosimilar), Exemptia (Adalimumab biosimilar), Vivitra (Trastuzumab biosimilar) and Bryxta (Bevacizumab biosimilar). Its Zydus biologics covers various therapeutic areas, such as oncology, autoimmune disease, nephrology, inflammation, rheumatology, hepatology and infectious illnesses, among others. The Company has a global presence and markets its products in the United States, India, Europe and emerging markets.

  • Revenue in INR (TTM)214.84bn
  • Net income in INR42.78bn
  • Incorporated1995
  • Employees26.24k
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Abbott India Ltd60.66bn12.85bn589.84bn3.81k45.9116.7543.489.72604.57604.572,854.721,657.051.275.3215.7115,904,690.0026.8220.9236.9728.5945.0944.2021.1817.261.71131.360.016977.069.359.7226.5221.6831.0852.32
Alkem Laboratories Ltd127.06bn21.22bn655.01bn17.28k30.865.7026.485.16177.51177.511,062.75961.220.79311.725.147,354,390.0013.4911.8818.6617.5063.1059.2617.0113.941.9712.210.110429.829.2111.4882.4718.75-13.3020.11
Aurobindo Pharma Ltd302.95bn35.82bn721.21bn8.80k20.262.3414.092.3861.2961.29518.43531.650.65851.276.0434,437,900.007.799.2411.0813.4358.7653.3011.8312.721.1013.690.21448.6416.688.1964.626.0617.9612.47
Lupin Ltd214.31bn26.26bn961.27bn21.87k36.706.1426.204.4957.4257.42468.54342.910.87611.354.489,800,284.0010.841.4316.642.2268.6058.5212.372.041.2211.880.179775.0320.256.41345.1530.18-1.179.86
Zydus Lifesciences Ltd214.84bn42.78bn970.36bn26.24k22.744.4518.854.5242.4142.66212.94216.890.74951.755.018,187,310.0015.009.0519.9614.0171.4361.1520.0114.331.58217.940.007816.4813.408.2395.2515.72-3.03-3.04
Dr Reddy's Laboratories Ltd300.85bn53.39bn1.01tn26.34k18.893.2814.513.3564.0364.03360.85369.120.73791.373.9011,420,450.0013.3111.3718.1416.0270.6965.8618.0314.631.3630.690.134915.9113.5412.6423.7523.3926.7814.87
Mankind Pharma Ltd110.18bn21.15bn1.05tn19.54k49.529.9040.759.4952.7052.70274.57263.690.87862.029.465,638,684.0017.05--21.79--70.48--19.41--2.3799.720.0428--18.12--49.23------
Torrent Pharmaceuticals Ltd112.25bn18.02bn1.11tn14.92k61.3414.7342.519.8553.2553.25331.63221.720.75251.226.357,525,369.0012.088.3417.9513.0375.5271.7816.0613.180.74449.320.294161.6511.516.9333.0230.58-8.1726.93
Cipla Ltd265.12bn44.75bn1.21tn27.76k27.144.2821.974.5855.3955.39328.19351.200.8031.585.089,549,060.0013.5810.0916.4412.4067.0158.6316.9212.662.8269.410.01621.3913.289.5147.1021.9620.6834.08
Data as of Nov 26 2024. Currency figures normalised to Zydus Lifesciences Ltd's reporting currency: Indian Rupee INR

Institutional shareholders

10.28%Per cent of shares held by top holders
HolderShares% Held
Life Insurance Corporation of India (Investment Portfolio)as of 08 Aug 202431.77m3.16%
ICICI Prudential Asset Management Co. Ltd.as of 31 Oct 202416.74m1.66%
Kotak Mahindra Asset Management Co. Ltd.as of 31 Oct 202415.30m1.52%
The Vanguard Group, Inc.as of 06 Nov 20249.28m0.92%
PPFAS Asset Management Private Ltd.as of 31 Oct 20248.15m0.81%
BlackRock Fund Advisorsas of 07 Nov 20246.07m0.60%
Nippon Life India Asset Management Ltd. (Invt Mgmt)as of 31 Oct 20244.64m0.46%
Norges Bank Investment Managementas of 30 Jun 20244.36m0.43%
Axis Asset Management Co. Ltd.as of 31 Oct 20243.77m0.38%
UTI Asset Management Co. Ltd. (Investment Management)as of 31 Oct 20243.34m0.33%
More ▼
Data from 30 Jun 2024 - 21 Nov 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.